• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, September 18, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Why two?

Bioengineer by Bioengineer
August 31, 2018
in Biology
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

FAT10 is a small protein with a huge effect. Its attachment to a target protein is a signal for its degradation. FAT10 is a marking system for degradation that seems to be inefficient. In contrast to its biological competitor, ubiquitin, which is recycled, FAT10 is degraded along with its target protein which appears wasteful at first glance.

So, why does this seemingly inefficient FAT10-system exist at all? Professor Marcus Groettrup, head of the immunology working group at the University of Konstanz, and his team have been carrying out research on FAT10 for many years. Now they achieved a break-through that made it possible to determine the high-resolution structure of FAT10. This success was enabled through another achievement. In collaboration with Dr Annette Aichem from the Biotechnology Institute Thurgau (BITg), Konstanz chemist Professor Christine Peter and structural biologist Dr Silke Wiesner from the University of Regensburg, the team developed a molecular technique to produce stable and highly-concentrated FAT10 with a high degree of purity. As a consequence, the researchers could carry out a structure analysis of FAT10 via x-ray crystallography and magnetic resonance spectroscopy. The results have been published in the current issue of Nature Communications.

"We found a mechanism in FAT10 that is entirely different from ubiquitin. This mechanism is very interesting for the entire ubiquitin field", says Marcus Groettrup. In contrast to ubiquitin with one domain, FAT10 has two domains, i.e. folds that enable the proteins to function. The team has now discovered that both domains are connected by a flexible linker and their folding is significantly less compact than in ubiquitin. Importantly, FAT10 has a short, disordered extension.

Experiments show that the loose folding and the disordered extension of the FAT10 protein have an important regulatory function that actually simplifies the degradation of the target molecule. As a result, no complicated upstream processes of partial substrate unfolding are necessary, as in the ubiquitin-system, to have the enzyme 26S proteasome, which actually carries out the degradation, spring into action. This is superfluous due to the loose folding of the FAT10 domains. The enzyme targets the disordered part and can easily unfold the two flexible and loosely folded domains, and consequently can pull apart the attached target protein and degrade it.

It had been already known before that ubiquitin and FAT10 have entirely different binding properties. That is all the more surprising, given the fact that the folding of both proteins' domains is based on the same structure. The findings of the research team now explain why: The surfaces of FAT10 and ubiquitin are entirely different, and they determine which proteins are bound. Consequently, both marking systems have different interaction partners. FAT10 is predominantly found in inflammatory tissue. "Without inflammation, it virtually is not present at all", says Marcus Groettrup. In his view it is an advantage that the marking system is destroyed along with the protein. His hypothesis: Nature counts on irreversibility in this context so the protein degradation cannot be reversed.

Another noticeable fact about FAT10: Marcus Groettrup: "In 13 different types of cancer it is found to an extended degree. We can conclude that FAT10 is advantageous for the cancer cells, for their survival and growth". If FAT10, for example, links to proteins that suppress tumour growth, they are degraded and the tumour cell can grow more easily. For such cases it is conceivable to develop a cancer drug inhibiting the enzymes that link FAT10 and the target proteins. "Talking about practical implementation, our findings actually provide grounds for hope", concludes Marcus Groettrup.

The project has been funded by the Collaborative Research Centre "Chemical and Biological Principles of Cellular Proteostasis" (SFB 969). The research on the marking system FAT10 and the results of the project will be used in the research area "ChemLife: Molecules in Functional Systems", one of the three cluster initiatives playing a major role in the University of Konstanz's application in the German Excellence Strategy competition.

###

Original publication:

Annette Aichem, Samira Anders, Nicola Catone, Philip Rößler, Sophie Stotz, Andrej Berg, Ricarda Schwab, Sophia Scheuermann, Johanna Bialas, Mira C. Schütz-Stoffregen, Gunter Schmidtke, Christine Peter, Marcus Groettrup & Silke Wiesner. The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation.
Nature Communications Volume 9, Article number: 3321 (2018)
https://doi.org/10.1038/s41467-018-05776-3

Facts:

  • Konstanz research team succeeds in stabilizing and analyzing the structure of the protein FAT10, a marking system to degrade target proteins
  • Research team: Biologist Professor Marcus Groettrup, chemist Professor Christine Peter (both University of Konstanz), structural biologist Dr Silke Wiesner from the University of Regensburg and Dr Annette Aichem from the Biotechnology Institute Thurgau
  • Fundamental research on the potential application as a cancer drug
  • Funded by the Collaborative Research Centre "Chemical and Biological Principles of Cellular Proteostasis" (SFB 969)
  • Continuation in the context of "ChemLife: Molecules in Functional Systems", one of the cluster initiatives at the University of Konstanz.
  • Further information on ChemLife can be found at: http://www.uni.kn/research/chemlife

Note to editors:

You can download photos here:

https://cms.uni-konstanz.de/fileadmin/pi/fileserver/2018/Bilder/Warum_zwei_Groettrup.jpg
Caption: Professor Marcus Groettrup
Photo: University of Konstanz

https://cms.uni-konstanz.de/fileadmin/pi/fileserver/2018/Bilder/Warum_zwei.jpg
Caption: FAT10 structure
Photo: Marcus Groettrup

Contact:
Communications and Marketing
Phone: + 49 7531 88-3603
Email: [email protected]

Media Contact

Julia Wandt
[email protected]
49-753-188-3603

https://cms.uni-konstanz.de/en/university-of-konst

https://www.uni-konstanz.de/en/university/news-and-media/current-announcements/press-releases/press-releases-in-detail/warum-zwei/

Related Journal Article

http://dx.doi.org/10.1038/s41467-018-05776-3

Share15Tweet8Share2ShareShareShare2

Related Posts

Bacterial Resistance to Heavy Metals and Chromium Reduction

Bacterial Resistance to Heavy Metals and Chromium Reduction

September 18, 2025
Could Enhancing This Molecule Halt the Progression of Pancreatic Cancer?

Could Enhancing This Molecule Halt the Progression of Pancreatic Cancer?

September 17, 2025

3D Jaw Analysis Uncovers Omnivorous Diet of Early Bears

September 17, 2025

Wild Chimpanzees Consume the Equivalent of Several Alcoholic Drinks Daily, Study Finds

September 17, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    155 shares
    Share 62 Tweet 39
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Atlantic Reef Decline Boosts Sea-Level Rise

Revolutionary Light-Powered Motor Miniaturized to the Size of a Human Hair

Children’s Psychosocial Recovery Post-ICU Hospitalization Studied

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.